http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190106981-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0987ba7c1b1ce300b1f141c5a1fc673f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 |
| filingDate | 2019-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef760c6c1bd1615774755f39793c8bc4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e02b8019cb17908e049bd6ff32da64e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a61a1dc4bce82bcfc412b5b6641ca6d5 |
| publicationDate | 2019-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20190106981-A |
| titleOfInvention | Controlled-release monolithic matrix tablets comprising bepotastine or its pharmaceutically acceptable salt and process for preparing the same |
| abstract | The present invention relates to bepotastine or a pharmaceutically acceptable salt thereof; Swellable polymers; And a release controlling single matrix tablet for daily administration, and a method for preparing the same, comprising a specific release controlling agent. The controlled release single matrix tablet of the present invention can be administered once a day by showing an immediate dissolution pattern in the early stage and a continuous dissolution pattern in the latter stage, and is independent of changes in gastrointestinal pH due to gastrointestinal environment and / or food. Elution can be achieved to minimize absorption variations. In addition, the controlled release single matrix tablet of the present invention exhibits bioequivalence with conventional formulations administered twice daily. In addition, controlled release single matrix tablets prepared according to the method of the present invention can effectively maintain the stability of bepotastine. |
| priorityDate | 2019-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.